Teligent PE Ratio 2012-2021 | TLGT
Current and historical p/e ratio for Teligent (TLGT) from 2012 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Teligent PE ratio as of May 20, 2026 is 0.00.
| Teligent PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2021-12-17 | 0.03 | 0.00 | |
| 2021-06-30 | 0.53 | $-7.24 | 0.00 |
| 2021-03-31 | 0.62 | $-9.66 | 0.00 |
| 2020-12-31 | 0.75 | $-14.67 | 0.00 |
| 2020-09-30 | 0.72 | $-8.63 | 0.00 |
| 2020-06-30 | 2.42 | $-9.87 | 0.00 |
| 2020-03-31 | 2.80 | $-8.05 | 0.00 |
| 2019-12-31 | 4.26 | $-4.67 | 0.00 |
| 2019-09-30 | 9.50 | $-6.36 | 0.00 |
| 2019-06-30 | 6.30 | $-5.74 | 0.00 |
| 2019-03-31 | 11.60 | $-7.50 | 0.00 |
| 2018-12-31 | 13.70 | $-6.80 | 0.00 |
| 2018-09-30 | 39.50 | $-5.20 | 0.00 |
| 2018-06-30 | 34.60 | $-6.20 | 0.00 |
| 2018-03-31 | 33.60 | $-3.90 | 0.00 |
| 2017-12-31 | 36.30 | $-2.80 | 0.00 |
| 2017-09-30 | 67.10 | $-2.80 | 0.00 |
| 2017-06-30 | 91.50 | $-1.60 | 0.00 |
| 2017-03-31 | 78.10 | $-1.90 | 0.00 |
| 2016-12-31 | 66.10 | $-2.30 | 0.00 |
| 2016-09-30 | 76.00 | $-1.20 | 0.00 |
| 2016-06-30 | 71.40 | $-1.20 | 0.00 |
| 2016-03-31 | 49.00 | $-1.00 | 0.00 |
| 2015-12-31 | 89.00 | $-0.70 | 0.00 |
| 2015-09-30 | 65.40 | $0.30 | 218.00 |
| 2015-06-30 | 63.00 | $0.80 | 78.75 |
| 2015-03-31 | 81.60 | $1.00 | 81.60 |
| 2014-12-31 | 88.00 | $0.90 | 97.78 |
| 2014-09-30 | 93.20 | $-0.18 | 0.00 |
| 2014-06-30 | 53.10 | $-0.20 | 0.00 |
| 2014-03-31 | 56.50 | $-0.20 | 0.00 |
| 2013-12-31 | 30.50 | $-0.30 | 0.00 |
| 2013-09-30 | 18.20 | $-0.52 | 0.00 |
| 2013-06-30 | 14.30 | $-0.90 | 0.00 |
| 2013-03-31 | 17.10 | $-0.90 | 0.00 |
| 2012-12-31 | 10.40 | $-1.00 | 0.00 |
| 2012-09-30 | 12.40 | $-0.90 | 0.00 |
| 2012-06-30 | 10.30 | $-0.60 | 0.00 |
| 2012-03-31 | 10.90 | $-0.70 | 0.00 |
| 2011-12-31 | 11.50 | $-0.80 | 0.00 |
| 2011-09-30 | 11.00 | $-0.50 | 0.00 |
| 2011-06-30 | 11.10 | $-1.20 | 0.00 |
| 2011-03-31 | 15.30 | $-1.60 | 0.00 |
| 2010-12-31 | 16.80 | $-2.00 | 0.00 |
| 2010-09-30 | 15.10 | $-2.60 | 0.00 |
| 2010-06-30 | 10.10 | $-2.30 | 0.00 |
| 2010-03-31 | 7.10 | $-4.00 | 0.00 |
| 2009-12-31 | 7.80 | $-4.60 | 0.00 |
| 2009-09-30 | 10.40 | $-4.40 | 0.00 |
| 2009-06-30 | 11.50 | $-4.30 | 0.00 |
| 2009-03-31 | 6.90 | $-2.50 | 0.00 |
| 2008-12-31 | 4.80 | $-1.20 | 0.00 |
| 2008-09-30 | 13.20 | $-0.70 | 0.00 |
| 2008-06-30 | 23.50 | $-0.40 | 0.00 |
| 2008-03-31 | 21.00 | 0 | 0.00 |
| 2007-12-31 | 14.10 | $-0.30 | 0.00 |
| 2007-09-30 | 10.00 | $-0.70 | 0.00 |
| 2007-06-30 | 7.50 | $-1.00 | 0.00 |
| 2007-03-31 | 8.50 | $-1.20 | 0.00 |
| 2006-12-31 | 11.60 | $-1.30 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.000B | $0.000B |
| Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |